PureTech Health provides the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.
It also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression delivers transformative medicines for patients with psychiatric and neurological conditions.
Additionally, it develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
PureTech Health plc is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases. Its pipeline includes LYT-100, a Phase 3-ready candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, which has the potential to become a new standard of care. The company is also developing LYT-200, a fully human IgG4 monoclonal antibody, and SPT-300, an oral prodrug of allopregnanolone for anxious depression. Additionally, PureTech is advancing a hydrogel platform for oral delivery of peptide therapeutics and oral therapies based on defined bacterial consortia, currently in Phase 3 clinical trials. The company operates primarily in the United States.
On which exchange is PureTech Health (PTCHF) listed and what currency is used?
PureTech Health plc is traded on the OTC Markets under the ticker symbol PTCHF, specifically on the OTCPK exchange. The trading currency is the US Dollar (USD). Although the company is incorporated in the United States and based in Boston, Massachusetts, its shares are available for trading on this over-the-counter market, which provides liquidity for investors outside major exchanges.
What sector and industry does PureTech Health (PTCHF) belong to?
PureTech Health plc operates in the Healthcare sector and is classified under the Biotechnology industry. This means the company is engaged in researching, developing, and commercializing biological and pharmaceutical products. Biotechnology firms like PureTech often focus on cutting-edge therapies, including monoclonal antibodies, prodrugs, and microbiome-based treatments, targeting conditions such as fibrotic diseases, psychiatric disorders, and neurological conditions.
Where is PureTech Health (PTCHF) headquartered and what markets does it serve?
PureTech Health plc is headquartered in Boston, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its description stating it provides biotechnology and pharmaceutical solutions in the United States. While its research and development activities are based in the U.S., the company's therapies aim to address global health challenges, particularly in fibrotic lung diseases, psychiatric conditions, and neurological disorders.
What are the key pipeline products of PureTech Health (PTCHF)?
PureTech Health's pipeline includes several notable therapeutic candidates. LYT-100 is a Phase 3-ready candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, designed to potentially establish a new standard of care. LYT-200 is a fully human IgG4 monoclonal antibody. SPT-300 is a Glyphed oral prodrug of allopregnanolone for anxious depression. The company also develops hydrogels for oral delivery of peptide therapeutics (preclinical) and oral therapies based on defined bacterial consortia, which are in Phase 3 clinical stage. These products target significant unmet medical needs in respiratory, psychiatric, and gastrointestinal areas.